25 Recruiting Studies Using Peripheral Blood Stem Cell
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Peripheral Blood Stem Cell
Delayed Tolerance Through Mixed Chimerism
📍 Massachusetts General Hospital — Boston, Massachusetts
Kidney Failure
View Study & Checklist ➔Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
📍 UC San Diego Moores Cancer Center — La Jolla, California
HIV Infection
View Study & Checklist ➔High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Chronic Granulomatous Disease Transplant
View Study & Checklist ➔Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
📍 M D Anderson Cancer Center — Houston, Texas
Acute Lymphoblastic Leukemia
View Study & Checklist ➔Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Aplastic Anemia
View Study & Checklist ➔Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
DS Stage I Multiple Myeloma
View Study & Checklist ➔Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
📍 Colorado Blood Cancer Institute — Denver, Colorado
Autoimmune Disease
View Study & Checklist ➔Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
📍 City of Hope Medical Center — Duarte, California
Acute Lymphoblastic Leukemia
View Study & Checklist ➔Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
📍 City of Hope Medical Center — Duarte, California
Recurrent Grade 1 Follicular Lymphoma
View Study & Checklist ➔Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
📍 Banner University Medical Center - Tucson — Tucson, Arizona
Acute Lymphoblastic Leukemia
View Study & Checklist ➔Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
📍 Memorial Sloan Kettering Cancer Center — New York, New York
Leukemia
View Study & Checklist ➔Allo HSCT Using RIC and PTCy for Hematological Diseases
📍 Masonic Cancer Center at University of Minnesota — Minneapolis, Minnesota
Acute Myelogenous Leukemia
View Study & Checklist ➔Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
📍 City of Hope Medical Center — Duarte, California
Acute Myeloid Leukemia With Complex Karyotype
View Study & Checklist ➔Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Primary Myelofibrosis
View Study & Checklist ➔Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Severe Aplastic Anemia (SAA)
View Study & Checklist ➔HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
📍 Memorial Sloan Kettering Cancer Center — New York, New York
Fanconi Anemia
View Study & Checklist ➔Stem Cell Transplantation in Crohn's Disease
📍 Cedars-Sinai Medical Center — Los Angeles, California
Crohn Disease
View Study & Checklist ➔A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
📍 Children's Hospital of Alabama — Birmingham, Alabama
Central Nervous System Nongerminomatous Germ Cell Tumor
View Study & Checklist ➔Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Recurrent T-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Auto Stem Cell Transplant for Lymphoma Patients
📍 Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota
Non-Hodgkin Lymphoma
View Study & Checklist ➔211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Acute Lymphoblastic Leukemia
View Study & Checklist ➔Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
📍 Moffitt Cancer Center — Tampa, Florida
Acute Leukemia
View Study & Checklist ➔211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Acute Lymphoblastic Leukemia in Remission
View Study & Checklist ➔Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Acute Leukemia of Ambiguous Lineage
View Study & Checklist ➔